Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PASKALIUM vs PASER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
Treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with other antituberculosis agents
Treatment of tuberculosis in combination with other antituberculosis drugs,Off-label: None
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (Cr Cl <10 m L/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine.
Hepatic via N-acetyltransferase (polymorphic acetylation); major metabolite is acetyl-PAS.
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Protein binding is approximately 10-15%, primarily to albumin. Binding is low, nonlinear, and saturable at high concentrations.
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity.
Volume of distribution is 0.5-0.7 L/kg, indicating distribution into total body water. Clinical meaning: Moderate distribution suggests penetration into well-perfused tissues but limited CNS penetration unless inflamed.
Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%.
Oral bioavailability is approximately 70-80% (range 60-90%). Food decreases the rate and extent of absorption, with AUC reduction of about 20-40%.
GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 4 g orally every 12 hours; monitor serum concentrations. Use with caution in moderate impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily.
No specific dose adjustment guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential hepatotoxicity; monitor liver function tests.
10 mg/kg/day orally in divided doses every 12 hours.
Not recommended for children (safety and efficacy not established).
Start at 250 mg daily; adjust based on renal function.
Lower initial doses may be considered due to age-related decline in renal function. Monitor renal function and serum concentrations closely.
None.
None
May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy.
May cause hypothyroidism, hepatitis, and crystalluria. Use with caution in patients with renal impairment or glucose-6-phosphate dehydrogenase deficiency.
Hypersensitivity to para-aminosalicylic acid or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min)
Hypersensitivity to para-aminosalicylic acid or any component; severe renal impairment.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes). Use of potassium-containing salt substitutes is contraindicated.
Take with food to reduce gastrointestinal irritation. Avoid high-fat meals as they may delay absorption. Avoid alcohol.
PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility.
PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Second and third trimesters: No known major malformations; risks may include gastrointestinal intolerance in mother. Advised use only if clearly needed.
Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported.
Excreted into breast milk in small amounts. M/P ratio unknown. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea or rash.
Pregnancy may alter potassium distribution due to increased plasma volume. Dosing should be individualized based on serum potassium levels. No fixed dose adjustment required; titrate to maintain normal potassium levels (3.5-5.0 m Eq/L).
No dosing adjustment required for pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) not significant for PASER; standard adult dose of 4 g twice daily is recommended.
PASKALIUM is a potassium-sparing diuretic used for hypertension and edema. Monitor serum potassium regularly; avoid in severe renal impairment or hyperkalemia. Coadministration with ACE inhibitors or NSAIDs increases hyperkalemia risk.
PASER (aminosalicylic acid) is a second-line antitubercular agent that inhibits folic acid synthesis. Administer with food to reduce GI upset; avoid concurrent use with salicylates due to additive GI irritation. Monitor for hepatotoxicity and hypersensitivity reactions. Drug levels should be monitored in patients with renal impairment.
Take exactly as prescribed; do not skip doses or double up.,Avoid potassium-rich foods and salt substitutes unless directed.,Report muscle weakness, irregular heartbeat, or signs of hyperkalemia.,May cause dizziness; avoid driving until effects known.
Take this medication with food to minimize stomach upset.,Do not crush or chew the tablets; swallow them whole.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems (yellowing of skin/eyes, dark urine) or allergic reactions (rash, fever) immediately.,Avoid alcohol during treatment.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PASKALIUM vs PASER, answered by our medical review team.
PASKALIUM is a Antitubercular Agent that works by PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.. PASER is a Antitubercular Agent that works by Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PASKALIUM and PASER depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PASKALIUM is: PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.. The standard adult dose of PASER is: 4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PASKALIUM and PASER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PASKALIUM is classified as Category C. PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcom. PASER is classified as Category C. PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.